26 results found.

Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage I Follicu Clinical Trial using cabozantinib-s-malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy.
cabozantinib-s-malate; laboratory biomarker analysis

Recurrent Thyroid Cancer Clinical Trial using lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer.
lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

Thyroid Cancer Clinical Trial using IMRT; DWI MRI

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer.
IMRT; DWI MRI

Differentiated Thyroid Cancer Clinical Trial using Selumetinib; Placebo; Radioactive Iodine Therapy

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer.
Selumetinib; Placebo; Radioactive Iodine Therapy

Differentiated Thyroid Cancer Clinical Trial using vandetanib; placebo

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy..
vandetanib; placebo

Multiple Endocrine Neoplasia Type 2A, or Multiple Endocrine Neopl Clinical Trial using ZACTIMA (Vandetanib)

National Institutes of Health Clinical Center (CC) - Recruiting 5 years to 18 years.
- Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma.
ZACTIMA (Vandetanib)

Hypopituitarism, Hypogonadism, Thyroid Dysfunction, or Bone Disea Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 24 years.
- Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoitic Stem Cell Transplant Recipients.

Thyroid Cancer, or Thyroid Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 16 years to 34 years.
- Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident.

Head and Neck Cancer Clinical Trial using everolimus; laboratory biomarker analysis

Yonsei University - Recruiting 18 years or older.
- An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer.
everolimus; laboratory biomarker analysis

Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyr Clinical Trial using dabrafenib; trametinib; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma.
dabrafenib; trametinib; Correlative Studies

Differentiated Thyroid Cancer (DTC), or Poorly Differentiated Thy Clinical Trial using Cabozantinib

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting.
Cabozantinib

Thyroid Neoplasms Clinical Trial using Ponatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer.
Ponatinib

Non-Medullary Thyroid Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years or older.
- Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer.

Solid Tumor, or Anaplastic Thyroid Cancer Clinical Trial using Cisplatin and Crolibulin; Cisplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC).
Cisplatin and Crolibulin; Cisplatin

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Neoplasm Metastasis, Thyroid Neoplasm, or Thyroid Nodule Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Studies on Thyroid Nodules and Thyroid Cancer.

Malignant Struma Ovarii, Papillary Thyroid Cancer, Hurthle Cell T Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone.

Medullary Thyroid Carcer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Longitudinal Assessment and Natural History Study of Children and Young Adults With Medullary Thyroid Carcinoma.

Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Pre Clinical Trial using sorafenib tosylate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 30 years.
- A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
sorafenib tosylate; pharmacological study; laboratory biomarker analysis

Papillary Thyroid Cancer, Follicular Thyroid Cancer, or Different Clinical Trial using SU011248, Sutent

Washington Hospital Center - Recruiting 18 years or older.
- Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.
SU011248, Sutent

Recurrent Thyroid Cancer, Stage I Follicular Thyroid Cancer, Stag Clinical Trial using cediranib maleate; lenalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
cediranib maleate; lenalidomide; laboratory biomarker analysis

Thyroid Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 35 years to 80 years.
- Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study.

Medullary Thyroid Cancer Clinical Trial using GI-6207

GlobeImmune - Recruiting 18 years or older.
- A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer.
GI-6207

Medullary Thyroid Cancer Clinical Trial using SOM230 alone or in combination with RAD001.

Federico II University - Recruiting 18 years to 80 years.
- Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression.
SOM230 alone or in combination with RAD001.

Thyroid Cancer Clinical Trial

Far Eastern Memorial Hospital - Recruiting 18 years to 90 years.
- An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules.

Differentiated Thyroid Cancer Clinical Trial using Everolimus; Sorafenib

University of Pennsylvania - Recruiting 18 years to 89 years.
- A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone.
Everolimus; Sorafenib